BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 11375890)

  • 1. Inhibition of HIF-1- and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions.
    Blagosklonny MV; Giannakakou P; Romanova LY; Ryan KM; Vousden KH; Fojo T
    Carcinogenesis; 2001 Jun; 22(6):861-7. PubMed ID: 11375890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperinducibility of hypoxia-responsive genes without p53/p21-dependent checkpoint in aggressive prostate cancer.
    Salnikow K; Costa M; Figg WD; Blagosklonny MV
    Cancer Res; 2000 Oct; 60(20):5630-4. PubMed ID: 11059752
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements.
    Campomenosi P; Monti P; Aprile A; Abbondandolo A; Frebourg T; Gold B; Crook T; Inga A; Resnick MA; Iggo R; Fronza G
    Oncogene; 2001 Jun; 20(27):3573-9. PubMed ID: 11429705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of wild-type p53 activity by mutant p53 R273H depends on the p53 responsive element (p53RE). A comparative study between the p53REs of the MDM2, WAFI/Cip1 and Bax genes in the lung cancer environment. WAFI/Cip1 = WAF1/Cip1.
    Zacharatos PV; Gorgoulis VG; Kotsinas A; Manolis EN; Liloglou T; Rassidakis AN; Kanavaros P; Field JD; Halazonetis T; Kittas C
    Anticancer Res; 1999; 19(1A):579-87. PubMed ID: 10226602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct promoter elements mediate the co-operative effect of Brn-3a and p53 on the p21 promoter and their antagonism on the Bax promoter.
    Perez-Sanchez C; Budhram-Mahadeo VS; Latchman DS
    Nucleic Acids Res; 2002 Nov; 30(22):4872-80. PubMed ID: 12433990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 inhibits hypoxia-inducible factor-stimulated transcription.
    Blagosklonny MV; An WG; Romanova LY; Trepel J; Fojo T; Neckers L
    J Biol Chem; 1998 May; 273(20):11995-8. PubMed ID: 9575138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
    Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
    Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of apoptosis by the p53-273L (Arg --> Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax.
    Kaneuchi M; Yamashita T; Shindoh M; Segawa K; Takahashi S; Furuta I; Fujimoto S; Fujinaga K
    Mol Carcinog; 1999 Sep; 26(1):44-52. PubMed ID: 10487521
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The chimeric E2A-HLF transcription factor abrogates p53-induced apoptosis in myeloid leukemia cells.
    Altura RA; Inukai T; Ashmun RA; Zambetti GP; Roussel MF; Look AT
    Blood; 1998 Aug; 92(4):1397-405. PubMed ID: 9694729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines.
    Aurelio ON; Kong XT; Gupta S; Stanbridge EJ
    Mol Cell Biol; 2000 Feb; 20(3):770-8. PubMed ID: 10629033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel p53 mutant retained functional activity in lung carcinomas.
    Ko JL; Chiao MC; Chang SL; Lin P; Lin JC; Sheu GT; Lee H
    DNA Repair (Amst); 2002 Sep; 1(9):755-62. PubMed ID: 12509279
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel human p53 mutations that are toxic to yeast can enhance transactivation of specific promoters and reactivate tumor p53 mutants.
    Inga A; Resnick MA
    Oncogene; 2001 Jun; 20(26):3409-19. PubMed ID: 11423991
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion.
    Fulci G; Ishii N; Maurici D; Gernert KM; Hainaut P; Kaur B; Van Meir EG
    Cancer Res; 2002 May; 62(10):2897-905. PubMed ID: 12019170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dominance of wild-type p53-mediated transcriptional activation in breast epithelial cells.
    Davis P; Bazar K; Huper G; Lozano G; Marks J; Iglehart JD
    Oncogene; 1996 Sep; 13(6):1315-22. PubMed ID: 8808706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of differential activation of target gene promoters by p53 hinge domain mutants with impaired apoptotic function.
    Kong XT; Gao H; Stanbridge EJ
    J Biol Chem; 2001 Aug; 276(35):32990-3000. PubMed ID: 11395510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of structural p53 mutants which show selective defects in apoptosis but not cell cycle arrest.
    Ryan KM; Vousden KH
    Mol Cell Biol; 1998 Jul; 18(7):3692-8. PubMed ID: 9632751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutant p53 proteins behave in a dominant, negative fashion in vivo.
    Hachiya M; Chumakov A; Miller CW; Akashi M; Said J; Koeffler HP
    Anticancer Res; 1994; 14(5A):1853-9. PubMed ID: 7847818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selective transcription of p53 target genes by zinc finger-p53 DNA binding domain chimeras.
    Falke D; Fisher MH; Juliano RL
    Biochim Biophys Acta; 2004 Nov; 1681(1):15-27. PubMed ID: 15566940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes.
    Willis A; Jung EJ; Wakefield T; Chen X
    Oncogene; 2004 Mar; 23(13):2330-8. PubMed ID: 14743206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.